Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults-Reference-Cited by-同舟云学术

Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults

Published:2013-06-24 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Linde Mattias¹²,Mulleners Wim M³,Chronicle Edward P⁴,McCrory Douglas C⁵⁶

Affiliation:

1. Norwegian University of Science and Technology; Department of Neuroscience; Trondheim Norway

2. St. Olav’s University Hospital; Norwegian Advisory Unit on Headaches; Trondheim Norway

3. Canisius Wilhelmina Ziekenhuis; Department of Neurology; PO Box 9015 Nijmegen Netherlands 6500 GS

4. University of Hawaii at Manoa; (Deceased) Department of Psychology; Manoa USA

5. Duke University Medical Center; Department of Medicine; Durham NC USA 27710

6. Durham Veterans Affairs Medical Center; Center for Health Services Research in Primary Care; 508 Fulton St Durham NC USA 27705

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD010609/fullpdf

Reference46 articles.

1. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study;Trapani;Clinica Terapeutica,2000

2. Effectiveness and safety of gabapentin in the preventive treatment of migraine;Jimenez-Hernandez;Revista de Neurologia,2002

3. Feuerstein T Quebe-Fehling E A double-blind, placebo-controlled, parallel-group, multicenter study of the safety and efficacy of gabapentin (CI-945) as a prophylactic interval therapy in patients with common migraine (Protocols 879-201, -205, -206, -207, -209) Research Report No. RR 4301-00066. Freiburg: Goedecke AG Research and Development; June 25, 1990. Available at: http://dida.library.ucsf.edu/pdf/crr13j10

4. Magnus-Miller L Bernstein P Caswell K Double-blind, randomized, placebo-controlled, multicenter trial to determine the efficacy and safety of Neurontin® (gabapentin) in migraine prophylaxis administered in doses divided three times a day (TID) (Protocol 945-220) Research Report No. RR 995-00074. Morris Plains, NJ: Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Medical and Scientific Affairs Department; August 24, 1999. Available at: http://dida.library.ucsf.edu/pdf/arr13j10

5. Magnus-Miller L Bernstein P Caswell K Double-blind, randomized, placebo-controlled, multicenter trial to determine the efficacy and safety of Neurontin® (gabapentin) in migraine prophylaxis (Protocol 945-217) Research Report No. RR 995-00085. Morris Plains, NJ: Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Medical and Scientific Affairs Department; January 20, 2000. Available at: http://dida.library.ucsf.edu/pdf/brr13j10

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aeromedical Risk of Migraine;Aerospace Medicine and Human Performance;2024-02-01

2. Migraine - a borderland disease to epilepsy: near it but not of it;The Journal of Headache and Pain;2024-01-26

3. Headache Management in Individuals with Brain Tumor;Seminars in Neurology;2024-01-06

4. Pregabalin inhibits purinergic P2Y2 receptor and TRPV4 to suppress astrocyte activation and to relieve neuropathic pain;European Journal of Pharmacology;2023-12

5. Gabapentinoids for the treatment of stroke;Neural Regeneration Research;2023-11-08